



REVIEWER'S REPORT

Manuscript No.: IJAR-52240

Date: 13/06/2025

Title: *Management of Membranous Glomerulonephritis-Efficacy of Mycophenolate Mofetil: A Case Report and Literature Review*

Recommendation:

- ✓ Accept as it is
- Accept after minor revision.....
- Accept after major revision
- Do not accept (*Reasons below*)

Rating	Excel.	Good	Fair	Poor
Originality		✓		
Techn. Quality		✓		
Clarity		✓		
Significance		✓		

Reviewer Name: Dr. S. K. Nath

Date: 13/06/2025

Reviewer's Comment for Publication:

The case demonstrates that MMF can induce remission and maintain renal function over long follow-up in idiopathic MGN, with a good safety profile. MMF appears to be a promising steroid-sparing alternative, especially for patients with contraindications to traditional immunosuppressants. However, further large-scale, controlled studies are needed to validate these findings and establish standardized treatment protocols.

Reviewer's Comment / Report

Strengths:

- **Detailed Case Presentation:** The paper provides in-depth clinical, histological, and follow-up data over eight years, illustrating the long-term efficacy and safety of MMF.
- **Comprehensive Literature Review:** Incorporates current research, including randomized trials and comparative studies, to contextualize MMF's role in MGN management.
- **Highlighting a Steroid-Sparing Approach:** Demonstrates that MMF can reduce steroid exposure, minimizing adverse effects.
- **Long-Term Follow-up:** Emphasizes durability of response and the importance of adherence, which adds robustness to the findings.
- **Potential Clinical Implication:** Suggests MMF as a viable treatment alternative in idiopathic MGN, especially considering its tolerability.

Weaknesses:

- **Single Case Report:** As with all case reports, the findings lack generalizability. Broader conclusions require larger studies.
- **Limited Comparative Data:** While a literature review is included, the paper does not present new randomized controlled trial (RCT) data directly comparing MMF to other immunosuppressants.
- **Possible Bias:** The positive outcome may be influenced by individual patient factors, and the response to MMF may not be uniform.
- **Lack of Standardized Protocols:** The paper mentions MMF and corticosteroid use without standardized dosing regimens, which could impact reproducibility.
- **Immunologic Workup:** The immunologic workup was negative, but the discussion about secondary causes and autoimmunity could be more detailed.